## Doron Gothelf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2062470/publications.pdf Version: 2024-02-01

		117625	114465
110	4,516	34	63
papers	citations	h-index	g-index
110	110	110	4571
113	113	113	4571
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Bridging the gap between the emergency department and outpatient care: feasibility of a short-term psychiatric crisis intervention for children and adolescents. European Child and Adolescent Psychiatry, 2023, 32, 631-637.	4.7	2
2	Parental Expressed Emotion, Parenting Stress, and Behavioral Problems of Young Children with 22q11.2 Deletion Syndrome and Idiopathic Autism Spectrum Disorder. Child Psychiatry and Human Development, 2023, 54, 1085-1093.	1.9	6
3	A normative chart for cognitive development in a genetically selected population. Neuropsychopharmacology, 2022, 47, 1379-1386.	5.4	12
4	Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome. European Child and Adolescent Psychiatry, 2022, 31, 1367-1375.	4.7	2
5	The Development of Somatic Symptom Disorder in Children: Psychological Characteristics and Psychiatric Comorbidity. Journal of the Academy of Consultation-Liaison Psychiatry, 2022, 63, 324-333.	0.4	3
6	Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome. World Journal of Biological Psychiatry, 2022, 23, 475-482.	2.6	2
7	Left alone outside: A prospective observational cohort study on mental health outcomes among relatives of COVID-19 hospitalized patients. Psychiatry Research, 2022, 307, 114328.	3.3	6
8	Keeping it simple: mental health assessment in the Gastroenterology Department – using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110664.	3.2	5
9	Editorial statement. European Child and Adolescent Psychiatry, 2022, , 1.	4.7	0
10	Sleep Difficulties Among COVID-19 Frontline Healthcare Workers. Frontiers in Psychiatry, 2022, 13, 838825.	2.6	4
11	The Feasibility of a Parent Group Treatment for Youth with Anxiety Disorders and Obsessive Compulsive Disorder. Child Psychiatry and Human Development, 2021, 52, 1044-1049.	1.9	4
12	Differential methylation of imprinting genes and MHC locus in 22q11.2 deletion syndrome-related schizophrenia spectrum disorders. World Journal of Biological Psychiatry, 2021, 22, 46-57.	2.6	10
13	Obsessive compulsive symptoms severity among children and adolescents during COVID-19 first wave in Israel― Journal of Obsessive-Compulsive and Related Disorders, 2021, 28, 100610.	1.5	36
14	The association between witnessing patient death and mental health outcomes in frontline COVIDâ€19 healthcare workers. Depression and Anxiety, 2021, 38, 468-479.	4.1	56
15	Delivering Difficult News: Simulation-Enhanced Training Improves Psychiatry Residents' Clinical Communication Skills. Frontiers in Psychiatry, 2021, 12, 649090.	2.6	5
16	The Delivery of Diagnosis by Child Psychiatrists: Process Characteristics and Correlates of Distress. Frontiers in Psychiatry, 2021, 12, 632207.	2.6	2
17	Minding the gap between clinical guidelines and real-life clinical work. European Child and Adolescent Psychiatry, 2021, 30, 681-683.	4.7	1
18	Trajectories of post-traumatic stress symptoms, anxiety, and depression in hospitalized COVID-19 patients: A one-month follow-up. Journal of Psychosomatic Research, 2021, 143, 110399.	2.6	63

#	Article	IF	CITATIONS
19	Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome – Clinical and scientific implications. Schizophrenia Research, 2021, 231, 164-169.	2.0	3
20	A binational study assessing risk and resilience factors in 22q11.2 deletion syndrome. Journal of Psychiatric Research, 2021, 138, 319-325.	3.1	5
21	Inter-rater reliability of subthreshold psychotic symptoms in individuals with 22q11.2 deletion syndrome. Journal of Neurodevelopmental Disorders, 2021, 13, 23.	3.1	1
22	Effectiveness of Metformin for Weight Reduction in Children and Adolescents Treated with Mixed Dopamine and Serotonin Receptor Antagonists: A Naturalistic Cohort Study. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 376-380.	1.3	2
23	Trajectories and risk factors for anxiety and depression in children and adolescents with cancer: A 1â€year followâ€up. Cancer Medicine, 2021, 10, 5653-5660.	2.8	11
24	Internalizing symptoms impede adolescents' ability to transition from in-person to online mental health services during the 2019 coronavirus disease pandemic. Journal of Telemedicine and Telecare, 2021, , 1357633X2110212.	2.7	4
25	Clinical Features in a Large Cohort of Patients With 22q11.2 Deletion Syndrome. Journal of Pediatrics, 2021, 238, 215-220.e5.	1.8	12
26	Relationship between intelligence quotient measures and computerized neurocognitive performance in 22q11.2 deletion syndrome. Brain and Behavior, 2021, 11, e2221.	2.2	8
27	Stimulant Treatment Effect on Anxiety Domains in Children with Attention-Deficit/Hyperactivity Disorder With and Without Anxiety Disorders: A 12-Week Open-Label Prospective Study. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 639-644.	1.3	1
28	Association among income loss, financial strain and depressive symptoms during COVID-19: Evidence from two longitudinal studies. Journal of Affective Disorders, 2021, 291, 1-8.	4.1	117
29	Is there a correlation between skull base flexure and palatal anomalies in patients with 22q11 deletion syndrome and velopharyngeal dysfunction?. Journal of Cranio-Maxillo-Facial Surgery, 2021, 49, 823-829.	1.7	0
30	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	7.9	87
31	Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review. European Child and Adolescent Psychiatry, 2020, 29, 1035-1048.	4.7	18
32	A retrospective case series of electroconvulsive therapy in the management of comorbid depression and anorexia nervosa. International Journal of Eating Disorders, 2020, 53, 210-218.	4.0	14
33	Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects. American Journal of Human Genetics, 2020, 106, 26-40.	6.2	42
34	Exploring the potential association among sleep disturbances, cognitive impairments, and immune activation in 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2020, 182, 461-468.	1.2	8
35	Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. International Clinical Psychopharmacology, 2020, 35, 300-304.	1.7	1
36	The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy. Journal of Molecular Neuroscience, 2020, 70, 1303-1312.	2.3	22

#	Article	IF	CITATIONS
37	Anxiety, pandemicâ€related stress and resilience among physicians during the COVIDâ€19 pandemic. Depression and Anxiety, 2020, 37, 965-971.	4.1	147
38	A threeâ€ŧier process for screening depression and anxiety among children and adolescents with cancer. Psycho-Oncology, 2020, 29, 2019-2027.	2.3	16
39	Anxiety and Depression Symptoms in COVID-19 Isolated Patients and in Their Relatives. Frontiers in Psychiatry, 2020, 11, 581598.	2.6	50
40	Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nature Medicine, 2020, 26, 1912-1918.	30.7	90
41	The interactive effects of test-retest and methylphenidate administration on cognitive performance in youth with ADHD: A double-blind placebo-controlled crossover study. Psychiatry Research, 2020, 291, 113056.	3.3	6
42	Physician Self-disclosure of Lived Experience Improves Mental Health Attitudes Among Medical Students: A Randomized Study. Journal of Medical Education and Curricular Development, 2020, 7, 238212051988935.	1.5	24
43	Single-Day Simulation-Based Training Improves Communication and Psychiatric Skills of Medical Students. Frontiers in Psychiatry, 2020, 11, 221.	2.6	9
44	Reducing Stigma Toward Psychiatry Among Medical Students. primary care companion for CNS disorders, The, 2020, 22, .	0.6	7
45	Education and employment trajectories from childhood to adulthood in individuals with 22q11.2 deletion syndrome. European Child and Adolescent Psychiatry, 2019, 28, 31-42.	4.7	21
46	Children's Friendship Training Program for Israeli elementary school age children with attention-deficit/hyperactivity disorder. Journal of Neural Transmission, 2019, 126, 1513-1516.	2.8	0
47	Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study. PLoS ONE, 2019, 14, e0217383.	2.5	13
48	Risk gene-set and pathways in 22q11.2 deletion-related schizophrenia: a genealogical molecular approach. Translational Psychiatry, 2019, 9, 15.	4.8	13
49	Electroencephalography Functional Networks Reveal Global Effects of Methylphenidate in Youth with Attention Deficit/Hyperactivity Disorder. Brain Connectivity, 2019, 9, 437-450.	1.7	1
50	The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder. International Clinical Psychopharmacology, 2019, 34, 179-183.	1.7	5
51	Obsessive–compulsive symptomatology in female adolescent inpatients with restrictive compared with binge–purge eating disorders. European Eating Disorders Review, 2019, 27, 224-235.	4.1	6
52	Psychiatric disorders and autism in young children with 22q11.2 deletion syndrome compared to children with idiopathic autism. European Psychiatry, 2019, 55, 116-121.	0.2	16
53	Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2. Human Molecular Genetics, 2018, 27, 1150-1163.	2.9	22
54	Endocrine manifestations in children with Williams–Beuren syndrome. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 678-684.	1.5	15

#	Article	IF	CITATIONS
55	Higher adaptive functioning and lower rate of psychotic comorbidity in married versus unmarried individuals with 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2365-2374.	1.2	3
56	The association between sleep disturbances of children with anxiety disorders and those of their mothers. Sleep Medicine, 2018, 43, 77-82.	1.6	6
57	Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. American Journal of Medical Genetics, Part A, 2018, 176, 2172-2181.	1.2	33
58	Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2182-2191.	1.2	51
59	Differences in demographic and clinical characteristics between cannabis users and non-drug users: A retrospective study of patients at first hospitalization due to psychotic symptoms. Psychiatry Research, 2018, 268, 454-459.	3.3	3
60	Medical, Cognitive, and Psychiatric Characteristics in a Large Israeli Cohort of Individuals with Williams Syndrome. Israel Medical Association Journal, 2018, 20, 373-378.	0.1	3
61	Testing the Efficacy of a Smartphone Application in Improving Medication Adherence, Among Children with ADHD. , 2018, 55, 59-63.		6
62	The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 83-90.	1.3	30
63	Negative subthreshold psychotic symptoms distinguish 22q11.2 deletion syndrome from other neurodevelopmental disorders: A two-site study. Schizophrenia Research, 2017, 188, 42-49.	2.0	16
64	Growth characteristics and endocrine abnormalities in 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 1301-1308.	1.2	15
65	Psychiatric and cognitive characteristics of individuals with Danon disease ( <i>LAMP2</i> gene) Tj ETQq1 1 0.7	'84314 rgB 1.2	BT /Qyerlock 1
66	Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study. Schizophrenia Bulletin, 2017, 43, 1079-1089.	4.3	47
67	Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits. Journal of Clinical Psychiatry, 2017, 78, e1219-e1225.	2.2	17
68	Do Antidepressants Induce Psychosis in Children and Adolescents? A Naturalistic Study in Ambulatory Pediatric Population. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 478-484.	1.3	5
69	Neurocognitive profile in psychotic versus nonpsychotic individuals with 22q11.2 deletion syndrome. European Neuropsychopharmacology, 2016, 26, 1610-1618.	0.7	45
70	Association between prematurity and the evolution of psychotic disorders in 22q11.2 deletion syndrome. Journal of Neural Transmission, 2016, 123, 1491-1497.	2.8	8
71	Performance on a computerized neurocognitive battery in 22q11.2 deletion syndrome: A comparison between US and Israeli cohorts. Brain and Cognition, 2016, 106, 33-41.	1.8	22
72	The outcome of children with selective mutism following cognitive behavioral intervention: a follow-up study. European Journal of Pediatrics, 2016, 175, 481-487.	2.7	27

#	Article	IF	CITATIONS
73	The link between parent and child sleep disturbances in children with attention deficit/hyperactivity disorder. Sleep Medicine, 2016, 21, 160-164.	1.6	8
74	Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome. Human Genetics, 2016, 135, 273-285.	3.8	43
75	Post-childhood Presentation and Diagnosis of DiGeorge Syndrome. Clinical Pediatrics, 2016, 55, 368-373.	0.8	9
76	Parents' and Teachers' Perceptions of Abnormal Attention Span of Elementary School-Age Children. Israel Journal of Psychiatry, 2016, 53, 33-38.	0.2	0
77	Thymic and bone marrow output in individuals with 22q11.2 deletion syndrome. Pediatric Research, 2015, 77, 579-585.	2.3	18
78	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	11.0	196
79	Copy-Number Variation of the Glucose Transporter Gene SLC2A3 and Congenital Heart Defects in the 22q11.2 Deletion Syndrome. American Journal of Human Genetics, 2015, 96, 753-764.	6.2	62
80	Hyperactive auditory processing in Williams syndrome: Evidence from auditory evoked potentials. Psychophysiology, 2015, 52, 782-789.	2.4	36
81	Assessing fears of preschool children with nighttime fears by a parent version of the fear survey schedule for preschool children. Israel Journal of Psychiatry, 2015, 52, 61-5.	0.2	0
82	The Outcome of Severe Internalizing and Disruptive Disorders from Preschool into Adolescence:A Follow-up Study. Israel Journal of Psychiatry, 2015, 52, 100-5.	0.2	0
83	Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2014, 171, 627-639.	7.2	645
84	Association of COMT and PRODH gene variants with intelligence quotient (IQ) and executive functions in 22q11.2DS subjects. Journal of Psychiatric Research, 2014, 56, 28-35.	3.1	22
85	Shyness discriminates between children with 22q11.2 deletion syndrome and Williams syndrome and predicts emergence of psychosis in 22q11.2 deletion syndrome. Journal of Neurodevelopmental Disorders, 2014, 6, 3.	3.1	17
86	Measuring Prodromal Symptoms in Youth With Developmental Disabilities: A Lesson From 22q11 Deletion Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 945-947.	0.5	4
87	Nighttime fears of preschool children: A potential disposition marker for anxiety?. Comprehensive Psychiatry, 2014, 55, 336-341.	3.1	16
88	Biological Effects of COMT Haplotypes and Psychosis Risk in 22q11.2 Deletion Syndrome. Biological Psychiatry, 2014, 75, 406-413.	1.3	63
89	Risk Factors and the Evolution of Psychosis in 22q11.2 Deletion Syndrome: A Longitudinal 2-Site Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1192-1203.e3.	0.5	108
90	Genotype-phenotype correlation in 22q11.2 deletion syndrome. BMC Medical Genetics, 2012, 13, 122.	2.1	83

#	Article	IF	CITATIONS
91	Developmental changes in multivariate neuroanatomical patterns that predict risk for psychosis in 22q11.2 deletion syndrome. Journal of Psychiatric Research, 2011, 45, 322-331.	3.1	64
92	Psychiatric Disorders and Intellectual Functioning Throughout Development in Velocardiofacial (22q11.2 Deletion) Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1060-1068.	0.5	253
93	Psychiatric morbidity with focus on obsessive–compulsive disorder in an Israeli cohort of adolescents with mild to moderate mental retardation. Journal of Neural Transmission, 2008, 115, 929-936.	2.8	28
94	Genes, brain development and psychiatric phenotypes in velo ardioâ€facial syndrome. Developmental Disabilities Research Reviews, 2008, 14, 59-68.	2.9	114
95	Association between cerebral shape and social use of language in Williams syndrome. American Journal of Medical Genetics, Part A, 2008, 146A, 2753-2761.	1.2	23
96	Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Annals of Neurology, 2008, 63, 40-51.	5.3	174
97	Risk Factors for the Emergence of Psychotic Disorders in Adolescents With 22q11.2 Deletion Syndrome. American Journal of Psychiatry, 2007, 164, 663-669.	7.2	214
98	Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. International Journal of Neuropsychopharmacology, 2007, 10, 301.	2.1	54
99	Velocardiofacial Syndrome. Child and Adolescent Psychiatric Clinics of North America, 2007, 16, 677-693.	1.9	70
100	Developmental trajectories of brain structure in adolescents with 22q11.2 deletion syndrome: A longitudinal study. Schizophrenia Research, 2007, 96, 72-81.	2.0	83
101	Abnormal cortical activation during response inhibition in 22q11.2 deletion syndrome. Human Brain Mapping, 2007, 28, 533-542.	3.6	52
102	Follow-up of preschool children with severe emotional and behavioral symptoms. Israel Journal of Psychiatry and Related Sciences, 2006, 43, 16-20.	0.5	1
103	Pilot Study: Fluvoxamine Treatment for Depression and Anxiety Disorders in Children and Adolescents with Cancer. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 1258-1262.	0.5	48
104	Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. American Journal of Medical Genetics Part A, 2004, 126B, 99-105.	2.4	130
105	Genetic, developmental, and physical factors associated with attention deficit hyperactivity disorder in patients with velocardiofacial syndrome. American Journal of Medical Genetics Part A, 2004, 126B, 116-121.	2.4	80
106	Life events and personality factors in children and adolescents with obsessive-compulsive disorder and other anxiety disorders. Comprehensive Psychiatry, 2004, 45, 192-198.	3.1	106
107	Schizophrenia in adolescent twins: a case study. Israel Journal of Psychiatry and Related Sciences, 2004, 41, 54-60.	0.5	0
108	Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Velocardiofacial Syndrome. Journal of Clinical Psychiatry, 2003, 64, 1163-1169.	2.2	73

#	ARTICLE	IF	CITATIONS
109	Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine. American Journal of Psychiatry, 2002, 159, 1055-1057.	7.2	223
110	Loneliness and Social Media Use Among Adolescents with Psychiatric Disorders. Cyberpsychology, Behavior, and Social Networking, 0, , .	3.9	1